Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Public ClinicalTrials.gov record NCT07108387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Study of Tocilizumab Discontinuation for Patients With Giant Cell Arteritis in Remission (AGA01)
Study identification
- NCT ID
- NCT07108387
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Interventions
- Discontinue Tocilizumab Drug
- Tocilizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2025
- Primary completion
- Jun 10, 2027
- Completion
- Jan 10, 2030
- Last update posted
- May 14, 2026
2025 – 2030
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University School of Medicine: Division of Rheumatology | Atlanta | Georgia | 30307 | Recruiting |
| Northwestern University | Chicago | Illinois | 60611 | Not yet recruiting |
| Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center | Baltimore | Maryland | 21287 | Recruiting |
| Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases | Boston | Massachusetts | 02114 | Recruiting |
| Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology | Great Neck | New York | 11021 | Recruiting |
| Hospital for Special Surgery, New York: Division of Rheumatology | New York | New York | 10021 | Not yet recruiting |
| University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology | Pittsburgh | Pennsylvania | 15217 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07108387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07108387 live on ClinicalTrials.gov.